临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
Breast cancer biomarkers,332–337 337
gene array as prognostic factor,267–268 268
health-related quality of life,397–398 398
Contract research organization (CRO),445,447 447
Council of International Organizations of Medical Sciences (CIOMS)adverse event classification,426 426
C-reactive protein (CRP)biology,345–346 346
biomarker applications atherosclerosis,349–351 351
inflammatory bowel disease levels,341 341
Crohn’s disease C-reactive protein levels,341 341
health-related quality of life,404–405 405
CTCAE dictionary adverse event severity grading,442–443 443
CTD see Common Technical Document Cumulative toxicity basis of exclusion,74–76 76
Cytokines see also specific cytokines classification,476–477 477
mechanism of action considerations in diseases with immune component,476–478 478
modulation of immune system,483–484 484
timing of questionnaires,386–387 387
Hematological cancers see also specific cancers acute lymphocytic leukemia,284–287 287
acute myeloid leukemia,289–291 291
acute promyelocytic leukemia,291–292 292
chronic lymphocytic leukemia,287–288 288
chronic myeloid leukemia,293–294 294